Circulating MicroRNA Expression Profiles in Patients with Stable and Unstable Angina

Sudong Liu, III,IV Xuemin Guo, III,IV Wei Zhong, I,II Ruiqiang Weng, III,IV Jing Liu, III,IV Xiaodong Gu, III,IV Zhixiong Zhong1,III,*

1Center for Cardiovascular Diseases, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou 514031, P. R. China. 2Center for Precision Medicine, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou 514031, P. R. China. 3Research Experimental Center, Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou 514031, P. R. China. 4Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou 514031, P. R. China.

OBJECTIVES: High incidence and case fatality of unstable angina (UA) is, to a large extent, a consequence of the lack of highly sensitive and specific non-invasive markers. Circulating microRNAs (miRNAs) have been widely recommended as potential biomarkers for numerous diseases. In the present study, we characterized distinctive miRNA expression profiles in patients with stable angina (SA), UA, and normal coronary arteries (NCA), and identified promising candidates for UA diagnosis.

METHODS: Serum was collected from patients with SA, UA, and NCA who visited the Department of Cardiovascular Diseases of the Meizhou People’s Hospital. Small RNA sequencing was carried out on an illumina HiSeq 2500 platform. miRNA expression in different groups of patients was profiled and then confirmed based on that in an independent set of patients. Functions of differentially expressed miRNAs were predicted using gene ontology classification and Kyoto Encyclopedia of Genes and Genomes pathway analysis.

RESULTS: Our results indicated that circulating miRNA expression profiles differed between SA, UA, and NCA patients. A total of 36 and 161 miRNAs were dysregulated in SA and UA patients, respectively. miRNA expression was validated by reverse transcription quantitative polymerase chain reaction.

CONCLUSION: The results suggest that circulating miRNAs are potential biomarkers of UA.

KEYWORDS: Coronary Artery Disease; MicroRNA (miRNA); Stable Angina; Unstable Angina; RNA sequencing (RNA-seq).

INTRODUCTION

Coronary artery disease (CAD) is a major global health problem (1), and the acute coronary syndrome (ACS), which is the most severe form of CAD, is the leading cause of death and disability worldwide (2,3). Early and accurate diagnosis of ACS is critical for effective treatment, for reducing cardiovascular events, and for improving disease prognosis.

CAD is a chronic inflammation which comprises several stages from chest pain to stable angina (SA) which may aggravate to more severe unstable angina (UA) or acute myocardial infarction (AMI) (4). AMI is diagnosed by angiography and plasma biomarkers such as cardiac troponin (5). However, relatively few specific biomarkers are available to distinguish UA from SA, which is critical, as UA is more likely to produce poor outcomes. Therefore, novel clinical biomarkers for early diagnosis of UA are required.

MicroRNAs (miRNAs) are endogenous RNAs with a length of approximately 22–24 nucleotides which post-transcriptionally control gene expression by targeting the 3’untranslated region of mRNA (6). It is estimated that miRNAs regulate about 60% of protein-coding genes that are involved in various biological processes such as cell growth, differentiation, and apoptosis (7). Many recent studies suggest that miRNAs play crucial roles in pathophysiological processes of cardiovascular diseases (8-10). Moreover, miRNA expression is associated with atherosclerotic plaque stability (11). miRNAs are tissue-specific and are traceable in the circulatory system, which makes them suitable as diagnostic biomarkers (12-14). Several studies suggested that certain miRNAs, i.e., miR-1, miR133a, miR-133b, and miR-499, are dysregulated in patients with cardiac injury and myocardial infarction (15-17). A different study showed that circulating miRNAs are promising diagnostic and prognostic UA biomarkers (18). However, only few biomarkers can be used to reliably distinguish UA from SA; therefore, research on miRNA candidates is needed to identify useful biomarkers for UA diagnosis.

*Corresponding author. E-mail: zhongzx@aliyun.com

Received for publication on September 26, 2019. Accepted for publication on April 7, 2020

DOI: 10.6061/clinics/2020/e1546

Copyright © 2020 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited. No potential conflict of interest was reported.
In the present study, we examined distinct miRNA profiles in plasma of SA and UA patients using high-throughput sequencing. The objective of this study was to identify specific miRNAs that can be used as biomarkers of UA.

**MATERIALS AND METHODS**

**Study subjects**

Subjects were recruited from all patients who attended the Department of Cardiovascular Diseases of the Meizhou People’s Hospital between January 1, 2017, and December 31, 2018. The study cohort included three groups, i.e., UA patients, SA patients, and patients with normal coronary arteries (NCA). Patients were diagnosed angiographically with CAD if at least one major epicardial vessel showed >50% stenosis. CAD patients were categorized as UA patients according to the 2014 AHA/ACC guidelines for management of ACS patients (19), or as SA patients according to the ACC/AHA guidelines (20). Patients with no observable stenosis in the coronary artery, as determined by coronary angiography, were considered NCA patients. Clinical history and medication records of patients were compiled, and subjects were excluded if they had a left ventricular ejection fraction of less than 45% or if they suffered from congestive heart failure, severe infectious diseases, or other malignant diseases.

**Ethics approval**

The study was approved by the Ethical Committee of the Meizhou People’s Hospital. Written informed consent was obtained from each subject.

**Sample collection**

Peripheral venous blood samples were collected after coronary angiography surgery. Blood samples were placed in EDTA-coated tubes. Plasma was separated by centrifugation at 1600 g and 4°C for 10 min. Supernatants were transferred to new tubes which were then centrifuged at 14,000 g and 4°C for 15 min to produce cell- and platelet-free plasma samples which were then stored at -80°C until further use.

**RNA extraction**

RNA was isolated from plasma using a QIAamp Circulating Nucleic Acid kit (Qiagen, Valencia, CA, USA) following the manufacturer’s instructions. The concentration and purity of the miRNAs were assessed using a NanoDrop-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). For normalization, Caenorhabditis elegans miR-39 (cel-miR-39) was added to plasma samples after addition of TRIzol, according to previously published study (21).

**Small RNA sequencing**

A total of 3 μg of qualified RNA was used for miRNA library preparation using a TruSeq Small RNA Library Preparation Kit (Illumina, San Diego, CA, USA). Briefly, 3’- and 5’-adaptors were ligated to miRNAs, followed by reverse transcription (RT) using RT primers. Complementary DNA (cDNA) was amplified, and the products were separated using polyacrylamide gel electrophoresis. Fragments containing 140–160 bp were recovered to produce cDNA libraries. Library concentration was measured using a Qubit 2.0 fluorometer (Thermo Fisher Scientific). cDNA libraries were sequenced on a HiSeq 2500 platform (Illumina). Raw reads were decoded and annotated as small RNAs and sequence data were bioinformatically analyzed according to established methods (22).

**RNA sequence data analysis**

Raw reads in fastq format were processed to remove low-quality reads, ambiguous nucleotides, adapter sequences, and poly-A tails to retain clean reads only. Pre-processed miRNA datasets were mapped to miRNA reference sequences using miRBase R19 software. Expression values of specific miRNAs were calculated as transcripts per million reads (TPM), according to the following equation:

$$TPM = \frac{(\text{read count} \times 1,000,000)}{\text{total read count}}$$

**Target gene analysis**

Putative targets of dysregulated miRNAs were predicted using the three databases miRanda, MicroCosm, and Targets-CAN. To improve prediction accuracy, we chose putative targets that were identified in all three databases. To further explore potential biological functions of miRNA targets, gene ontology (GO) terms classifications and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed. GO classification (regarding biological processes, cellular components, and molecular functions) was carried out using the software Database for Annotation Visualization and Integrated Discovery (42). Pathway analyses were performed using the KEGG database. In brief, enriched biological processes, cellular components, molecular functions, and signaling pathways were selected through hyper-geometric tests and Fisher’s tests after mapping the potential target genes to the dataset of GO terms and KEGG pathways. A false discovery rate <0.05 was considered statistically significant.

**Validation of miRNA expression**

miRNA expression was detected using a Bulge-Loop miRNA qRT-PCR Starter Kit (RiboBio Co., Ltd, Guangzhou, China), according to the manufacturer’s instructions. Briefly, 1 μg miRNA was used for RT in a polymerase chain reaction (PCR) thermocycler at 42°C for 42 min and 70°C for 10 min. A quantitative real-time PCR (qPCR) reaction mix (20 μl) containing 2 μl RT product, 10 μl SYBR Green mix, 0.8 ul primers and 6.4 ul distilled water (RiboBio Co., Ltd, Guangzhou, China) was prepared, and amplification was carried out on a Roche LightCycler 480 instrument (Roche, Mannheim, Germany). cel-miR-39 was used as a spike-in reference, as is common practice (23,24). The delta cycle threshold (ΔCt) of miRNAs of interest was calculated using the following equation: ΔCt = C[miRNA of interest] - C[cel-miR-39]. miRNA expression was calculated using the 2\(^{-\Delta\DeltaCt}\) method with an arbitrary value of 1 for the control group.

**Statistical analyses**

Data were analyzed using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA). Student’s t-test was applied to test differences between two groups. A one-way ANOVA followed by Tukey’s post-hoc test was used to test differences between more than two groups; p-values <0.05 were considered statistically significant.

**RESULTS**

**Clinical characteristics**

Nineteen patient samples were subjected to small RNA sequencing. Basic clinical characteristics of these patients are
Dysregulated miRNA expression profiles in UA and SA patients

A total of 1,314 miRNAs were identified, including 987 annotated and 327 novel miRNAs. A hierarchical cluster analysis indicated distinct miRNA expression profiles in UA, SA, and NCA patients (Figure 1A). To identify differentially expressed miRNAs, we used selection criteria of a fold change $\geq 2$ and a $p$-value $<0.05$. A total of 161 miRNAs were dysregulated in UA compared to NCA, 105 of which were upregulated and 56 were downregulated; 36 miRNAs were differentially expressed in SA compared to NCA, 27 of which were upregulated and 9 were downregulated (Figure 1B). In total, 150 miRNAs were unique to the UA group, and 25 miRNAs were unique to the SA group. UA and SA groups shared 11 differentially expressed miRNAs (Figure 1C).

GO functional analysis and KEGG pathway analysis

GO functional analysis was performed to reveal the biological functions of target genes of dysregulated miRNAs between UA, SA, and NCA patients. Target genes of dysregulated miRNAs in SA patients were involved in biological

Table 1 - Clinical characteristics of patients. Means ± standard deviations are shown in each case.

| Variables          | NCA (n=5) | SA (n=6) | UA (n=8) | $p$-value$^*$ |
|--------------------|-----------|----------|----------|---------------|
| Age (years)        | 57 ± 8.71 | 63 ± 9.88 | 61 ± 7.97 | 0.53          |
| Sex M/F            | 2 (40%)   | 4 (66.7%) | 5 (62.5%) | 0.63          |
| SBP (mmHg)         | 133 ± 9.51| 134.7 ± 12.71 | 132.9 ± 11.42 | 0.95          |
| DBP (mmHg)         | 84.6 ± 2.07| 81.8 ± 13.24 | 78.4 ± 5.7 | 0.45          |
| Lipid profile      |           |           |          |               |
| TG (mmol/L)        | 0.99 ± 0.43| 1.1 ± 0.60 | 2.5 ± 0.81 | <0.01         |
| TC (mmol/L)        | 4.43 ± 0.91| 4.41 ± 0.74 | 4.43 ± 0.63 | 1.00          |
| HDL-C (mmol/L)     | 1.40 ± 0.41| 1.27 ± 0.16 | 1.02 ± 0.22 | 0.06          |
| LDL-C (mmol/L)     | 2.26 ± 0.51| 2.55 ± 0.73 | 2.48 ± 0.53 | 0.71          |
| Risk factors       |           |           |          |               |
| Active smoker (n, %)| 1 (20%)   | 1 (16.7%) | 4 (50%)  | 0.34          |
| Drink (n, %)       | 1 (20%)   | 1 (16.7%) | 1 (12.5%) | 0.93          |
| Hypertension (n, %)| 1 (20%)   | 1 (16.7%) | 2 (25%)  | 0.93          |
| Dyslipidemia (n, %)| 1 (20%)   | 0 (0%)    | 5 (62.5%)| 0.04          |
| Diabetes mellitus (n, %)| 1 (20%) | 0 (0%) | 2 (25%) | 0.43          |
| Drug administration|           |           |          |               |
| Aspirin (n, %)     | 2 (40%)   | 5 (83%)  | 4 (50%)  | 0.29          |
| Clopidogrel (n, %) | 1 (20%)   | 3 (50%)  | 5 (62.5%)| 0.32          |
| Statin (n, %)      | 2 (40%)   | 6 (100%) | 7 (87.5%)| 0.04          |
| ACEI (n, %)        | 2 (40%)   | 4 (67.7%)| 6 (75%) | 0.63          |

$^*$Comparisons between groups were performed using a one-way ANOVA for continuous variables and with a Chi-square test for categorical variables.

SA, stable angina; UA, unstable angina; NCA, normal coronary arteries; M/F, male/female; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor.

Figure 1 - Differentially expressed miRNAs in patients with SA, UA, and NCA. (A) Cluster analysis of differentially expressed miRNAs in patients with SA, UA, and NCA. (B) Upregulated and downregulated miRNAs in patients with SA and UA. (C) Venn diagram of differentially expressed miRNAs in SA and UA patients compared with those of NCA patients. SA, stable angina (SA); UA, unstable angina; NCA, normal coronary artery.
processes such as cellular metabolism, cellular macromolecule metabolism, multicellular organismal development, and other biological processes (Figure 2A), whereas in UA patients, targets of dysregulated miRNAs were associated with biological processes such as protein phosphorylation, transcription, DNA-dependent, cell adhesion (Figure 2B).

Furthermore, KEGG analysis revealed that dysregulated miRNAs in the SA group were associated with pathways such as MAPK signaling, B cell receptor signaling, and apoptosis (Figure 3A), whereas differentially expressed miRNAs in UA group were associated with the Wnt, PI3K – Akt, and MAPK pathways (Figure 3B).

Validation of differentially expressed miRNAs
To assess expression of miRNAs, we randomly selected eight miRNAs and examined their expression by RT-qPCR (Table 2). Expression of these miRNAs was assessed in independent sets of patients with UA (n=15), SA (n=15), and NCA (n=15), and the expression pattern was different in UA and SA patients as compared to that in NCA patients.

Figure 2 - GO terms analysis of differentially expressed miRNAs in SA and UA patients compared with NCA patients. (A) Enriched GO terms of differentially expressed miRNAs in SA patients compared with NCA patients. (B) Enriched GO terms of differentially expressed miRNAs in UA patients compared with NCA patients. The top-20 GO terms of biological processes, cellular components, and molecular functions are shown. Each GO term has a corrected p-value < 0.05. GO, gene ontology; SA, stable angina (SA); UA, unstable angina; NCA, normal coronary artery.

Figure 3 - KEGG pathway analysis of differentially expressed miRNAs in SA and UA patients compared with NCA patients. (A) Enriched top-20 pathways of differentially expressed miRNAs in SA patients compared with NCA patients. (B) Enriched top-20 pathways of differentially expressed miRNAs in UA patients compared with NCA patients. Rich factor: the ratio of candidate genes enriched in the pathway to total genes in the pathway. KEGG, Kyoto Encyclopedia of Genes and Genomes; SA, stable angina (SA); UA, unstable angina; NCA, normal coronary artery.
DISCUSSION

We examined expression profiles of circulating miRNA in patients with UA, SA, and NCA. Our results revealed that SA and UA patients had different miRNA profiles compared with NCA patients; most dysregulated miRNAs occurred at higher levels in SA and UA patients than in NCA patients, and UA patients showed more dysregulated miRNAs than SA patients.

ACS is still one of the most severe threats to global public health (25,26). UA is a major form of ACS, however, only few specific biomarkers are available for diagnosis. Therefore, non-invasive sensitive biomarkers of UA are urgently required. miRNAs occur in body fluids and remain stable even under severe conditions (27-29). These characteristics make them ideal candidates as noninvasive biomarkers for many diseases. Recent studies suggest that miRNAs are potential diagnostic biomarkers of cardiovascular diseases such as heart failure (30) and AMI (16). A different study showed that miR-499-5p can be used to distinguish congestive heart failure from non-ST-segment elevation myocardial infarction patients (31). Moreover, miR-135a, miR-378, and miR-147 are effective biomarkers of CAD (32), and miR-208b, miR-499, and miR-1 are associated with the development of ACS and can thus be used as biomarkers of AMI (33). In the present study, we found 36 miRNAs that were dysregulated in SA patients and 161 in UA patients. These miRNAs may be attributed to the progression of CAD. Moreover, 11 miRNAs were dysregulated in both SA and UA patients. These consistently dysregulated miRNAs may be strongly associated with the development of CAD and thus appear to be particularly promising candidates for early detection of ACS.

miRNAs regulate gene expression. We, therefore, predicted the functions of differentially expressed miRNAs using GO terms classification and KEGG pathway analysis. We found that differentially expressed miRNAs regulated inflammation-associated processes such as cell adhesion and the MAPK signaling pathway (34,35). Furthermore, the Wnt pathway, which was also targeted in our study, is involved in endothelial injury, macrophage activation, and vascular smooth muscle migration, and these processes are closely associated with onset and progression of atherosclerosis (36).

Previous studies showed that miR-1 is associated with cardiac injury and cardioprotection, and is increased in patients suffering from AMI (37). miR-142 is increased in atherosclerotic plaques and regulates oxLDL-induced apoptosis in macrophages; moreover, it can be used to predict major adverse cardiovascular events in CAD patients (38). In line with these observations, we observed increased levels of miR-1-3p and miR-142-3p in SA and UA patients, compared to those in NCA patients, which suggested their correlation with CAD progression.

**Table 2** - Dysregulated miRNAs in patients with UA and SA compared to those of NCA patients.

| miRNAs     | log_{2}FC | p Value | Regulation | log_{2}FC | p Value | Regulation |
|------------|-----------|---------|------------|-----------|---------|------------|
| miR-7109-3p| 6.28      | 0.0005  | up         | 4.96      | 0.0020  | up         |
| miR-6515-3p| 4.00      | 0.0025  | up         | 4.10      | 0.0069  | up         |
| miR-1273g-3p| 3.36     | 0.0013  | up         | 3.45      | 0.0020  | up         |
| miR-20b-5p | 3.30      | 0.00032 | up         | 2.55      | 0.013   | up         |
| miR-6783-5p| 2.86      | 0.0013  | up         | 2.77      | 0.0173  | up         |
| miR-142-3p | 2.45      | 0.0002  | up         | 2.46      | 0.0109  | up         |
| miR-6783-5p| 2.44      | 0.00365 | up         | 2.44      | 0.01    | up         |

SA, stable angina; UA, unstable angina; NCA, normal coronary artery; FC, fold change.
Currently, there is no consensus regarding internal references for circulating miRNAs. U6 was used as a reference in some studies, but it easily degrades in serum (39). However, miR-16 and miR-1228 are consistently expressed in serum (40,41). In the present study, we observed that miR-16 expression varied between patients, and miR-1228 was decreased in UA patients. Recently, non-human spike-in miRNAs such as cel-mir-39 and cel-mir-67 have been commonly used as alternative references for normalization (21,23). Therefore, we used cel-mir-39 to normalize miRNA levels between different subjects.

There are some limitations of the present study which should be noted. Firstly, we profiled miRNA expression in SA and UA patients, however, we were unable to identify miRNAs that can be used to distinguish UA from SA. Secondly, white blood cells have not been examined in the present study, which may bias the generated profiles of circulating miRNAs.

In conclusion, we identified distinct circulating miRNA expression profiles in patients with UA and SA by small RNA sequencing. Dysregulated miRNAs were functionally associated with pathogenesis of CAD and are thus promising non-invasive biomarkers for early diagnosis of UA.

ACKNOWLEDGMENTS

This study was supported by Medical Scientific Research Foundation of Guangdong Province, China (B2019213); Key Scientific and Technological Project of Meizhou People’s Hospital (MPHKSTP-20170101 and MPHKSTP-20170102).

AUTHOR CONTRIBUTIONS

Liu S and Guo X contributed to the data collection and manuscript writing. Weng R and Liu J contributed to data analyses. Zhong W, Weng R, Liu J and Gu X contributed to data collection. Liu S and Zhong Z conceived and planned the study, contributed to the data collection and analysis, and manuscript writing.

REFERENCES

1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e164-e603. https://doi.org/10.1161/CIR.0000000000000445
2. Falk E, Nakano M, Benton JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2013;34(10):719-28. https://doi.org/10.1093/eurheartj/eht411
3. Oevelmans MI, Mesterd A, Dekker MS, de Vrey EA, van Mil A, Pasterkamp G, et al. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating miRNAs. EMBO Mol Med. 2012;4(11):1176-85. https://doi.org/10.1002/emmm.201201749
4. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004-13. https://doi.org/10.1056/NEJMra1211063
5. Zeller T, Keller T, Ojeda F, Reichlin T, Twerenbold R, Tzikas S, et al. Non-Coding RNAs Including miRNAs and IncRNAs in Cardiovascular Biology and Disease. Cells. 2014;3(3):883-98. https://doi.org/10.3390/cells3030883
6. van Rooij E. The art of microRNA research. Circ Res. 2011;108(2):219-34.
7. Zeller T, Keller T, Ojeda F, Reichlin T, Twerenbold R, Tzikas S, et al. Non-Coding RNAs Including miRNAs and IncRNAs in Cardiovascular Biology and Disease. Cells. 2014;3(3):883-98. https://doi.org/10.3390/cells3030883
8. Corsten MF, Denuart R, Jochens S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3(6):499-506. https://doi.org/10.1161/CIRCGENETICS.110.957415
9. D’Alessandra Y, Devanna P, Limana F, Straino D, Di Carlo A, Brambilla PG, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31(22):2765-73. https://doi.org/10.1093/eurheartj/ehq167
10. Bostjancic E, Zidar N, Stajer D, Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2010;115(3):163-9. https://doi.org/10.1159/000266888
11. Pilbrow AP, Cordeddu L, Cameron VA, Frampton CM, Troughton RW, Doughty RN, et al. Circulating miR-323-3p and miR-652: candidate markers for the presence and progression of acute coronary syndromes. Int J Cardiol. 2014;176(2):275-85. https://doi.org/10.1016/j.ijcard.2014.07.020
12. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344-42.
13. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Pfiesterive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44-e164. https://doi.org/10.1016/j.jacc.2012.07.013
14. Karakas M, Schulte C, Appelbaum S, Oeffer F, Lackner KJ, Munzel T, et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study. Eur Heart J. 2017;38(7):516-23. https://doi.org/10.1093/euheartj/ehw250
15. Farrazi TA, Brown M, Morozov P, Ten Hoeve JJ, Ben-Dov IZ, Hovestadt V, et al. Bioinformatic analysis of barcoded cDNA libraries for small RNA profiling by next-generation sequencing. Methods. 2012;58(2):171-87. https://doi.org/10.1016/j.ydbio.2012.07.020
16. Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, et al. Serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015;16(7):804-15. https://doi.org/10.1016/S1470-2045(15)(00484-0
17. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5):677-84. https://doi.org/10.1161/CIRCRESAHA.109.215566
18. McManus DD, Lin H, Tanriverdi K, Quercio M, Yin X, Larson MG, et al. Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. Heart Rhythm. 2014;11(4):663-9. https://doi.org/10.1016/j.hrthm.2014.01.018
19. Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;127(6):749-56. https://doi.org/10.1161/CIR.0000000000000481
20. Mayr M, Zampetaki A, Willett P, Willett J, Kiechel S. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol. 2013;33(2):206-14. https://doi.org/10.1161/ATVBAHA.112.301041
21. Ajit SK. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors. 2012;12(3):3359-69. https://doi.org/10.3390/s120303359
22. Cortez MA, Bueno-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calvin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(9):467-77. https://doi.org/10.1038/nrclinonc.2011.76
23. Tijssen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR242-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035-9. https://doi.org/10.1161/CIRCRESAHA.110.218297
31. Olivieri F, Antonicelli R, Lorenzi M, D’Alessandra Y, Lazzarini R, Santini G, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol. 2013;167(2):531-6. https://doi.org/10.1016/j.ijcard.2012.01.075
32. D’Alessandra Y, Carena MC, Spazzafumo L, Martinelli F, Bassetti B, Devanna P, et al. Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. PLoS One. 2013;8(11):e80345. https://doi.org/10.1371/journal.pone.0080345
33. Peng L, Chun-guang Q, Bei-fang L, Xue-zhi D, Zi-hao W, Yun-fu L, et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. Diagn Pathol. 2014;9:89. https://doi.org/10.1186/1746-1596-9-89
34. Reustle A, Torzewski M. Role of p38 MAPK in Atherosclerosis and Aortic Valve Sclerosis. Int J Mol Sci. 2018;19(12):3761. https://doi.org/10.3390/ijms19123761
35. Zhong L, Simard MJ, Huot J. Endothelial microRNAs regulating the NF-kB pathway and cell adhesion molecules during inflammation. PASEB J. 2018;32(8):4070-84. https://doi.org/10.1096/fasebj.201701536R
36. Matthijs Blankesteijn W, Hermans KC. Wnt signaling in atherosclerosis. Eur J Pharmacol. 2015;768(Pt A):122-30. https://doi.org/10.1016/j.ejphar.2015.05.023
37. Kura B, Kaloczyova B, Devaux Y, Bartekova M. Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection. Int J Mol Sci. 2020;21(3):700. https://doi.org/10.3390/ijms21030700
38. Tang QJ, Lei HP, Wu H, Chen JY, Deng CY, Sheng WS, et al. Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy. Acta Pharmacol Sin. 2019;40(2):208-15. https://doi.org/10.1016/j.apsl.2018.09.004
39. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997-1006. https://doi.org/10.1038/cr.2008.282
40. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56(1):167-75. https://doi.org/10.1016/j.jhep.2011.04.026
41. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781-8. https://doi.org/10.1200/JCO.2011.38.2697
42. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):P3.